Innovent Presents Clinical Data of Phase I Study for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Solid Tumors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting ...Middle East

SAN FRANCISCO and SUZHOU, China, June 5, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic,...

Hence then, the article about innovent presents clinical data of phase i study for ibi351 kras g12c inhibitor as monotherapy for solid tumors at the 2022 american society of clinical oncology asco annual meeting was published today ( Monday 06/06/2022 - 03:20 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Presents Clinical Data of Phase I Study for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Solid Tumors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting )

Also on site :

• Russia-Ukraine war: List of key events, day 1,426
• Rangers’ Cody Bradford Targeting Return In May From Elbow Surgery
• '90s Trash Metal Band Releases New Single Ahead of Farewell Album